Radiologic Management of Haemoptysis: Diagnostic and Interventional Bronchial Arterial Embolisation

Radiologisches Management von Hämoptysen: Diagnostik und Interventionelle Bronchialarterienembolisation

H. Ittrich1, H. Klose2, G. Adam1

1 Diagnostic and Interventional Radiology Department and Clinic, Center for Radiology and Endoscopy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 Department of Internal Medicine II and Clinic – Section Pneumology, Center for Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Key words
- haemoptysis
- bronchial artery embolization (BAE)
- DSA
- multidetector computed tomography (MSCT)

Abstract
Hemoptysis can be a life-threatening pulmonary emergency with high mortality, is symptomatic of an underlying severe pulmonary disease and requires immediate diagnosis and treatment. Diagnostically, bronchoscopy, conventional chest x-ray and contrast-enhanced multislice computed tomography (MSCT) with CT angiography (CTA) provide information regarding the underlying pulmonary disease, bleeding site, the vascular anatomy of the bronchial arteries (BA) and extrabronchial branches, as well as a basis for planning of endovascular intervention. Therapeutically, bronchial artery embolization (BAE) is a safe and effective technique in the hands of an experienced interventionist with profound knowledge of the BA anatomy and possible pitfalls as well as experience with first-line therapy of recurrent and massive hemoptysis or as an intervention prior to elective surgery. Recurrent episodes of hemoptysis are not uncommon and require a prompt repeat BAE after exclusion of extrabronchial systemic and pulmonary artery bleeding sources. This review article should give an overview of the history, anatomical and pathophysiological basics and the clinical context of hemoptysis and diagnosis, as well as a survey of management, treatment and results of BAE.

Key Points:
- Hemoptysis are life threatening and require urgent diagnostic and therapy.
- Chest x-ray, bronchoscopy, and contrast-enhanced MSCT with CTA should be carried out before therapeutic bronchial artery embolization (BAE).
- BAE for the treatment of massive and recurrent hemoptysis is safe and effective.
- False embolization in spinal branches of BA are the most serious complication of a BAE.
- Repeatedly BAE refractory cases should undergo elective surgery.

Zusammenfassung

Kernaussagen:
- Hämoptysen sind lebensbedrohlich und erfordern eine dringende Diagnostik und Therapie.
- Thorax-Röntgen, Bronchoskopie und eine Kontrastmittel-unterstützte MSCT mit CTA sollten vor therapeutischer Bronchialarterienerembolisation (BAE) erfolgen.
- Die BAE zur Therapie von massiven und rezidivierenden Hämoptysen ist sicher und effektiv.
Introduction

Hemoptysis represents a life-threatening emergency situation requiring immediate diagnosis and therapy. This situation occurs frequently in clinical practice and requires a prompt investigation of the underlying cause as well as a rapid therapeutic response. Despite substantial advances in intensive care in recent decades, massive hemoptysis remains a clinical challenge both to diagnosis and therapy [1, 2]. Purely conservative treatment of massive hemoptysis results in a 50–100% mortality [3], while asphyxia from intrabronchial blood accumulation rather than blood loss is the cause of death [4] in most of these cases. Up until the 1990s, the therapy of choice for hemoptysis was surgery. The mortality in cases of intermittent hemoptysis was between 7 and 18%; mortality rates for emergency surgeries were between 37 and 42% [5–7].

A minimally-invasive procedure using bronchial artery embolization (BAE) was first introduced at the start of the 1970s [8], and in the past 3 decades has been recognized as the most effective and safe non-surgical procedure for primary therapy of massive or recurring hemoptysis as well as for patient stabilization prior to elective surgery [9–15]. Surgery has maintained its therapeutic value in the case of special indications, such as traumatic injury to pulmonary vessels, bronchial adenoma, or therapy-resistant aspergilloma [16]. This article will provide an overview of the history, clinical background, anatomy and pathophysiology, diagnosis of massive hemoptysis and related therapy using BAE.

History

The existence of the bronchial arteries (BA), the internal vessels of the lung has been known since before the time of Galen (129 – 199 A.D.); these have been illustrated by artists such as Leonardo da Vinci [17]. In the 1960s, non-selective angiography of the thoracic aorta was first used to image pulmonary and pulmonary vascular anatomy [18, 19]. In 1963 Viramonte first described the angiography of the bronchial arteries [20]. This technique was first used to differentiate benign and malignant pulmonary space consumption and to determine the extent of bronchiectases [20–22]. In many cases this procedure resulted in transverse myelitis [23, 24]. The first successful selective BAE to treat hemoptysis was performed in France by Remy et al. in 1974 [25]. Since then, numerous authors have presented various techniques and related results.

Anatomical and pathophysiological principles

The lungs possess a dual blood supply via the pulmonary arteries, which in pulmonary circulation provide gas exchange with the alveoli and make up about 99% of arterial supply, and the bronchial arteries, which as internal vessels provide the remaining 1% of the supply [26]. That latter extend along the bronchi and subdivide into supplying branches to the trachea, the bronchi, the vasa vasorum of the pulmonary arteries and veins as well as to the aorta, to the small bronchopulmonary branches of the lung, diaphragmatic and mediastinal visceral pleura as well as to the central esophagus and subcarinal lymph nodes [17, 27, 28]. In a healthy subject, the bronchial arteries at the ostium measure less than 1.5 mm, and less than 0.5 mm at the entrance to the bronchopulmonary segment [28]. Bronchial artery diameter greater than 2 mm in CT is generally classified as abnormal [29]. Between the pulmonary and bronchial arteries there are numerous bronchopulmonary anastomoses on the bronchial and lobular level which maintain a physiological right-left shunt of approx. 5% of the cardiac output and have a size of up to 325 μm [27, 28]. Venous drainage occurs by means of the bronchopulmonary shunts via the pulmonary veins as well as regularly via the bronchial veins into the azygos vein, hemiazygos vein and superior vena cava [17]. Furthermore, shunts to the coronary arteries have been described which have been incidentally detected during a coronary MDCT or angiography as congenital or post-operatively acquired fistulas from the coronary arteries to the bronchial arteries; these occur with a frequency of 0.61% [30–37], and can be the cause of anginal symptoms due to a steal effect [38]. Similarly, bronchial artery fistulas with reversed flow to the coronary arteries have been described; these can potentially lead to severe cardiac complications in the course of bronchial artery embolization [39–42].

The origin of and supply to the lungs via the bronchial arteries are variable (Fig. 1). About 70% of the bronchial arteries emanate from the descending thoracic aorta between the end plate of the 5th thoracic vertebra and the base of the 6th thoracic vertebra [17, 26], frequently at the height where the aorta crosses the left main bronchus. The remaining 30% of bronchial arteries originate from other vascular territories such as the subclavian artery, internal thoracic artery, pericardiacoephrenic artery, inferior phrenic artery, thyrocervical trunk, brachiocephalic artery, the vertebral artery, the front of the aortic arch, the abdominal aorta or, in rare cases, the left gastric artery [17, 43, 44]. In the majority of cases, the right bronchial artery, together with the right-side intercostal artery forms a common intercostal bronchial trunk (ICBT) which is less frequently to be found on the left side. It should be noted that the ICBT can have a variable shape, and in 5–10% of known cases can branch into the anterior spinal artery (ASA) of the spinal cord [4, 45]. The typical supply to the anterior portion of the spinal cord is via the ASA, which is fed by branches from the intercostal and lumbar arteries. In this case, the anterior spinal arteries follow a typical “hairpin” course with an ascending portion that enters a descending intraspinal segment via a sharp bend (passing through the neural foramen) before draining into the ASA. The largest spinal artery is the artery radicularis magna, also known as the Adamkiewicz artery, which originates between the T8 and L4 vertebral segments, but can also in rare instances originate from a point as high as the 5th thoracic vertebra [17]. Knowledge of anatomical supply relationships of the bronchial and anterior spinal arteries as well as their variants should be considered fundamental for successful endovascular BAE therapy as well as to prevent fatal misembolization (e.g. ASA with spinal ischemia).

Citation Format:
Ittrich H et al. Radiologic Management of... Fortschr Röntgenstr 2015; 187: 248–259
Proliferation and enlargement of the bronchial arteries are the compensatory consequence of the expression of neoangiogenetic growth factors in cases of restriction of pulmonary circulation caused by hypoxic vasoconstriction, pulmonary thromboembolism or thrombosis, vasculitis or chronic inflammatory lung diseases [4, 28, 46–48]. Since their walls are thinner and more fragile, these blood vessels are subject to systemic arterial pressure and are located in a region susceptible to chronic inflammation. They rupture more frequently with bleeding into the airways which is clinically exhibited as massive hemoptysis [28, 49].

Clinical background

Angiographic and bronchoscopic studies as well arterial oxygenation of expectorated blood have demonstrated that the bronchial arteries are the primary origin of hemoptysis [10]. There are multiple causes of hemoptysis (Table 1). Most commonly hemoptysis occurs in the setting of chronic inflammatory pulmonary diseases, predominantly in cases of tuberculosis and as the result of aspergillus-populated cavities [11], but also may be caused by bronchiectasis resulting from chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF, lifetime risk – 4%) [50], pneumoconiosis, bronchogenic or iatrogenic tumors (e.g. after endobronchial coil implantation (EBRC)), Fig. 2.

In rare instances, hemoptysis is caused by bleeding from the pulmonary arteries caused by a rupture of congenital, infectious or vascular pathological pulmonary artery aneurysm or a pulmonary arteriovenous fistula (PAVM) [47, 51]. Hemoptysis resulting from a rupture of bronchial arterial (pseudo-) aneurysms is likewise a rarity [52–57]. Although most episodes of hemoptysis with low expectoration volumes can be treated with simple bed rest and supportive therapy, uncontrollable hemoptysis has a high mortality rate due to asphyxia and exsanguination. In the literature, massive hemoptysis has been defined to be between 100–1000 ml / 24 hours [4, 5, 47, 58]; however, between 300 and 600 ml of bloody expectoration in 24 hours is generally considered to be massive [47]. With a tracheobronchial tree volume of 150–200 ml, 300–400 ml of blood in the alveolar space can lead to significant gas exchange inhibition and death through asphyxia [16] long before blood loss results in volume deficiency shock [2].

In the era prior to endovascular intervention, bronchial artery embolization therapy consisted of surgical resection of the hemorrhaging pulmonary lobe if there were no contraindications for lobectomy such as lack of blood flow localization, inadequate vital capacity of the lung or inoperable bronchial carcinoma [9].

<table>
<thead>
<tr>
<th>Causes of hemoptysis.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>pulmonary disease</strong></td>
</tr>
<tr>
<td>malignant tumor</td>
</tr>
<tr>
<td>bronchitis</td>
</tr>
<tr>
<td>bronchiectasis</td>
</tr>
<tr>
<td>sarcoidosis</td>
</tr>
<tr>
<td>chronic obstructive pulmonary disease (COPD)</td>
</tr>
<tr>
<td>pneumonia</td>
</tr>
<tr>
<td>tuberculosis</td>
</tr>
<tr>
<td>aspergilloma</td>
</tr>
<tr>
<td>pulmonary abscess</td>
</tr>
<tr>
<td>cystic fibrosis</td>
</tr>
<tr>
<td>pneumoconiosis</td>
</tr>
<tr>
<td>lupus pneumonia</td>
</tr>
<tr>
<td><strong>cardiovascular disease</strong></td>
</tr>
<tr>
<td>pulmonary arteriovenous malformation (PAVM)</td>
</tr>
<tr>
<td>pulmonary embolism</td>
</tr>
<tr>
<td>pulmonary hypertension</td>
</tr>
<tr>
<td>aortic/bronchial arterial aneurysm</td>
</tr>
<tr>
<td>pulmonary arterial aneurysm (Rasmussen aneurysm)</td>
</tr>
<tr>
<td>vasculitis (Wegener’s granulomatosis, Behçet’s syndrome, Osler-Weber-Rendu disease, Goodpasture syndrome)</td>
</tr>
<tr>
<td>aortobronchial fistula</td>
</tr>
<tr>
<td><strong>other causes</strong></td>
</tr>
<tr>
<td>iatrogenic (after needling, pleural drainage)</td>
</tr>
<tr>
<td>iatrogenic after endobronchial coil implantation (EBRC)</td>
</tr>
<tr>
<td>coagulopathy/coagulation disorder</td>
</tr>
<tr>
<td>trauma</td>
</tr>
<tr>
<td>foreign body</td>
</tr>
<tr>
<td>congenital pulmonary or cardiovascular abnormality</td>
</tr>
</tbody>
</table>

---

Fig. 1  Variants in the bronchial artery anatomy ([26, 36]): A Typ I with 2 BA left (LBA) and 1 BA right (RBA) from ICBT in 40,6 %, B Typ II with 1 LBA (from Aorta) and 1 RBA (from ICBT) in 21,3 %, C Typ III with 2 LBA (from Aorta) and 2 RBA (from ICBT + Aorta) 20,6 % and D Typ IV with 1 LBA (from Aorta) and 2 RBA (from ICBT + Aorta) 9,7 %.

Abb. 1  Varianten in der Bronchialarterienanatomie (modifiziert nach [26, 36]): A Typ I mit 2 linken BA (LBA) und 1 rechten BA (RBA) aus dem ICBT in 40,6 %, B Typ II mit 1 LBA (aus Aorta) und 1 RBA (aus ICBT) in 21,3 %, C Typ III mit 2 LBA (aus Aorta) und 2 RBA (aus ICBT + Aorta) 20,6 % und D Typ IV mit 1 LBA (aus Aorta) und 2 RBA (aus ICBT + Aorta) 9,7 %.
Currently bronchial artery embolization is the therapy of choice for the treatment of massive and recurring hemoptysis [12, 59].

Diagnosing hemoptysis

In clinical routine, the two main diagnostic objectives in cases of hemoptysis are localization and identification of the cause of bleeding. Methods for this include a sputum analysis, hemostasis laboratory, bronchoscopy as well as chest X-ray as a thoracic overview radiograph on 2 planes or a contrast-enhanced multislice computed tomography (MSCT) with CT angiogram of the thorax. The sputum should be examined for the presence of bacteria (especially mycobacteria and fungus) as well as for malignant cells [16].

The hemostasis laboratory provides insight into the patient’s cellular and plasmatic coagulation situation. A promptly performed bronchoscopy (BSK) supports finding the cause and side localization of the bleeding [16, 60], although correct side localization of the bleeding can be achieved in only about half the patients [58, 61]. This can be performed easily and quickly as an initial fiber optic examination (fiber optic bronchoscopy – FOB) and as a rigid bronchoscopy in the case of more massive hemoptysis. Even in cases of heavy hemorrhaging, this can ensure a better overview, improved conditions for hemostasis, and oxygenation via jet ventilation. An advantage of bronchoscopy is the possibility of applying vasoactive substances to stanch the bleeding. The disadvantages of bronchoscopy in an acute bleeding situation include poor visibility due to endobronchial blood and the frequently ineffective therapeutic options [16, 58]. Additional risks of bronchoscopy include air passage restriction by the bronchoscope, respiratory depression resulting from sedation, hypoxemia, as well as time lost until a definitive therapy can be found.

The typical chest X-ray should be a thoracic overview image in 2 planes in order to detect frequent causes such as pneumonia, pulmonary abscesses, bronchial carcinoma or acute or chronic pulmonary tuberculosis.

Compared to bronchoscopy, a conventional thoracic X-ray examination can obtain additional information in about only half of patients [62]. Today, a thoracic CT scan should be performed in addition to bronchoscopy, due to the improved information that imaging technology can provide to localize bleeding (63 – 100 % accuracy in identifying the proper lobe) [61, 63], as well as to disclose the cause of hemoptysis. This is supported by low-dose acquisition methods (automatic tube current modulation(ACM)) for longitudinal and angle modulation [64, 65] and iterative image reconstruction methods (e.g. iDose4 (Philips), ADMIRE/SAFE/IRIS (Siemens), ASIR (GE). Compared to a standard thorax image on 2 planes with an effective dose of 0.1 – 0.2 mSv, a thoracic CT examination can be performed with an effective dose of 0.5 – 1.5 mSv [66 – 71]. Further, this scan can be performed rapidly and promptly, a significant advantage in the case of marginally stable patients. Compared to a conventional X-ray, the added value of contrast-enhanced multidetector CT (MDCT) systems, optionally equipped with EKG triggering to minimize pulsation artifacts of the thoracic vessels consists in improved detection of bronchiectasis (in cases of COPD or CF), bronchial carcinoma, aspergiloma [62, 72], pulmonary arteriovenous malformations (PAVM) as well as aneurysms of the thoracic or pulmonary arteries. MDCT also provides useful information regarding the anatomy, origin and course of the bronchial arteries as well as the course of aberrant bronchial arteries [73, 74]. Improved visualization of pulmonary pathologies and surgical planning can be achieved using numerous post-processing techniques such as multiplanar reconstruction (MPR), maximum intensity projection (MIP) or 3-dimensional (3D) volume and surface displays (shaded surface display (SSD)). It has been demonstrated
that a combination of bronchoscopy and MDCT provides the best results for the diagnosis of hemoptysis [63]. However, there is a question regarding the sequence of bronchoscopy and MDCT when diagnosing hemoptysis. Current studies indicate the advantages of performing MDCT prior to bronchoscopy [16, 75–77]. Conventional angiography using digital subtraction angiography (DSA) is utilized in the primary diagnosis of the bronchial arteries, however it is seldom used and is mainly employed for therapeutic bronchial artery embolization.

Management of hemoptysis

The management of hemoptysis primarily consists in monitoring and stabilizing the cardiopulmonary situation through correction of hypoxia, blood pressure stabilization and, if needed, substitution with blood products. In cases of massive hemoptysis, intensive monitoring of the patient and early endotracheal intubation (unilateral as needed) is preferred [1]. The therapeutic effectiveness of endobronchial installation of a cold saline solution, epinephrine or bronchial occlusion using a balloon catheter is limited [1, 60].

Until the 1970s, in addition to bronchoscopic localization to one body side, the therapy of choice was resection of the bleeding pulmonary lobe: however the mortality rate of such intervention as an elective measure was 18.2 %, and under emergency conditions was as high as 40 % due to the risk of hemorrhaging during surgery, asphyxia, bronchopulmonary fistulas or respiratory insufficiency [5, 78]. Complicating this type of surgical intervention on patients with massive hemoptysis are pre-existing conditions and limited respiratory reserve. Surgical therapy remains the first choice in cases of iatrogenic pulmonary artery injury, thoracic trauma or therapy-resistant aspergilloma [16, 79].

Interventional therapy

Although mild or moderate hemoptysis is frequently controlled using conservative therapy (antibiosis, discontinuation of non-steroidal antibiotics (NSAID), or therapeutic bronchial artery embolization (installation of cold saline solution, vasoconstrictors), see Guidelines for CF Patients [50], bronchial artery embolization (BAE) is considered the method of choice in cases of both massive and recurring hemoptysis [5, 10, 12, 80], and should be undertaken promptly. In cases of hemoptysis with malignant origin (bronchial carcinoma, metastasis), bronchial artery embolization is strongly indicated, since the mortality rate among mild and degenerative patients (affecting 90 % of patients) is significantly higher (21 %) that for hemoptysis with benign origin (5 %) [62, 81–83]. The goal of this approach is to reduce the systemic arterial perfusion pressure from the fragile bronchial arteries within the diseased lung parenchyma, thus staunching the bleeding [4]. When performing bronchial artery embolization, it should be noted that such patients usually suffer from chronic pulmonary disease and with dyspnea which can significantly worsen in a horizontal lying position (for angiography) and as a result of the hemoptysis. It must be further taken into account that the procedure must be repeatedly interrupted by the necessity to clear the airways due to expectorated blood. Although it is useful to use an oxygen mask for oxygenation of the patient during bronchial artery embolization, in individual cases selective intubation in the main bronchus contralateral to the bleeding is necessary to keep the airways open.

A neurological examination should be performed prior to bronchial artery embolization. Further, during the intervention, monitoring of the motor and sensory functions of the lower extremities should be ensured. Studies have shown that spinal complications resulting from BAE (e.g. ischemia) can be detected by highly-sensitive monitoring of somatosensory evoked potentials (SSEPs) [84]. Moderate sedation and administration of anxiolytics to the patient can facilitate the bronchial artery embolization, but should not impair the respiratory function, response and communication skills.

Technology

In general BAE should be performed by a radiologist experienced in intervention and embolization techniques in a clinic with a high-resolution digital subtraction angiography (DSA) unit. Under sterile conditions and after local anesthesia of one groin, a 5-French (F) vascular sheath is introduced via a transfemoral access route. By means of a suitable 4F or 5F catheter (e.g. pigtail catheter) placed in the proximal descending aorta, thoracic overview images are acquired using digital subtraction angiography (DSA) using mechanical contrast agent injection (e.g. iodine-based contrast agent, injection quantity: 30 ml, injection flow: 20 ml/second). Several projections should be acquired (anteroposterior, left anterior oblique (LAO) and right anterior oblique (RAO)) to obtain a systematic representation of the bronchial arterial outlets from the aorta. Then following the Seldinger technique, using a 0.035 guide wire, the ostia of all bronchial arteries are located with an appropriate 4F or 5F catheter (Cobra, Miakelson, Simmons, Shepherd Hook, Headhunter, Sidewinder or SOS Omni) and displayed using a selective DSA with manual injection of approx. 5–6 ml contrast agent. The ostium of the right bronchial artery can facilitate the bronchial artery embolization, but should not impair the respiratory function, response and communication skills.

Fig. 3 Normal bronchial arteries with vessel diameters up to 1.5 mm. As a variant the right (RBA) and left BA (LBA) origin from a common trunk from the aorta and directly adjacent, the origin of the 1st intercostal branch (1st ICA), (Intubated intensive care patient with blocked balloon catheter in the right main bronchus due to right endobronchial lung bleeding).

Abb. 3 Normale Bronchialarterien mit Gefäßdiametern bis 1,5 mm. Als Normvariante kommuner Abgang der rechten (RBA) und linken BA (LBA) origin from a common trunk from the aorta and directly adjacent, the origin of the 1st intercostal branch (1st ICA), (Intubated intensive care patient with blocked balloon catheter in the right main bronchus due to right endobronchial lung bleeding).
The left bronchial artery typically originates ventrally from the descending aorta at the level of the 4th–8th thoracic vertebra. As described above, the ICBT is the most frequent source of branches supplying the spine [17]. In addition to avoiding direct occlusion of the ICBT by the catheter itself, the use of small quantities of low osmolar contrast agent reduces the risk of spinal ischemia [12, 45].

Selective display of the bronchial arteries (Fig. 3) can assess the potential for a possible source of bleeding of the bronchial artery as well as identifying possible branches supplying the spine. Active bleeding which can be recognized by extravasation from a branch of the bronchial artery can be demonstrated in about 3.6–10.8% of cases and then only during an episode of massive hemoptysis [61, 85, 86]. The diameter of the bronchial arteries in cases of chronic inflammatory pulmonary disease is generally between 2–3 mm [17], however it can be several millimeters, especially in patients with cystic fibrosis (Fig. 4). Indicators of a diseased bronchial artery and source of hemoptysis include expansion of the bronchial artery diameter over 2 mm, a highly tortuous course of the bronchial artery, the presence of systemic pulmonary arterial or venous shunts, contrast agent extravasation, hypervascularization zones or aneurysms [12, 85, 87]. Upon indisputable identification of a pathologically altered bronchial artery, the artery should be embolized after excluding branches supplying the spine or contrasting the anterior spinal arteries, and after risk assessment of a possible systemic embolism (Fig. 5). To ensure a stable position and safe application of the bronchial artery embolization material distal to the arteries supplying the spine, a coaxial technique is employed using a 4F or 5F guidance catheter positioned securely in the ostium of the bronchial artery through which a 2–3F microcatheter system is introduced as distally as possible into the artery [4, 5]. Due to elongation of the bronchial artery and normal variation, the distance of the outlets of spinal branches measured from their aortal origin vary substantially, so that no general recommendation can...
be made with respect to the depth of the microcatheter probing into the bronchial artery to reach a safe application site; consequently this must be determined individually [88]. It must also be emphasized that spinal branches cannot be visualized prior to selective BAE, and can only become visible in the course of embolization as a result of blood flow redistribution [88 - 90]. After selective DSA of the bronchial artery using manual injection of a contrast agent (1 – 2 ml) and careful avoidance of the blood vessels feeding the spine distal to the end of the catheter (particularly ICBT on the right side) a bronchial artery embolization should be performed, taking into account the clinical, bronchoscopic, CT and angiographic findings ( Fig. 6). In the course of this procedure, reflux of embolisate into the aorta or branches supplying the spine with consecutive arterial misembolization must absolutely be avoided. This risk can be reduced by means of an incremental BAE with intermittent selective control DSA via the microcatheter [88, 90]. A bronchial artery embolization is successful if more than 95 % of the peripheral vascular branches have been embolized or if retrograde blood flow within the bronchial artery has been suspended [91]. The additional DSA of both subclavian arteries as well as of the lower thoracic aorta with the phrenic arteries (in cases of lower
lobe manifestations) excludes transpleural collaterals from aberrant bronchial arteries as a source of bleeding (Fig. 7). A subsequent thoracic aortogram with no contrasting of arterial branches supplying the lung is indicative of a successful BAE. If, despite successful bronchial artery embolization of all arterial feeders or in the case of normal, non-pathologically configured pulmonary arteries, continued or recurrent hemoptysis appears, then evaluation of the pulmonary arterial circulatory pathway is necessary [47] in order to rule out pulmonary arterial aneurysms or pulmonary arteriovenous malformations (PAVM) which are present in 5–10.5% of cases of hemoptysis [59, 92, 93]. The primary cause of bleeding from the pulmonary arterial circulatory area is Rasmussen’s aneurysm which is a pseudoaneurysm of an erosion of a peripheral pulmonary artery resulting from chronic inflammation, typically cases of chronic exudative cavernous pulmonary tuberculosis. Diagnosis is best achieved using a contrast-supported CT which shows contrast agent-enriched nodules and aneurysms in the wall of a tubercular cavern [94].

**Embolization material**

There are numerous options regarding material used for bronchial artery embolization or blockage of PAVM (Table 2). In the 1980s and 1990s, surgical gelatin sponges (Gelfoam) were employed since they are quite inexpensive and easy to use, but often cause only temporary occlusion due to resorption. Currently initial embolization preferably utilizes flow-directed, non-resorbable, permanently occluding polyvinyl alcohol-based (PVA) particles larger than 250 microns or cross-linking gelatin particles (tris-acryl gelatin microspheres (TAGM) [12, 95–98] (Fig. 8). Due to its more uniform diameter and hydrophilic surface, TAGM exhibits less clumping and microcatheter occlusion [98]. It was shown that the 12-month success rate, i.e. suppress-

Table 2  BAE embolization material.

<table>
<thead>
<tr>
<th>particle embolisate</th>
<th>form</th>
<th>vessel blockage</th>
<th>size [µm]</th>
<th>trade name</th>
<th>source</th>
</tr>
</thead>
<tbody>
<tr>
<td>gelatin sponge</td>
<td>amorphous, manually</td>
<td>temporary</td>
<td>variable</td>
<td>Gelfoam®</td>
<td>Baxter Health Care Corporation</td>
</tr>
<tr>
<td>PVA foam particle</td>
<td>irregular</td>
<td>permanent</td>
<td>90–2800</td>
<td>PVA foam embolization particles</td>
<td>Cook Medical</td>
</tr>
<tr>
<td>PVA foam particles</td>
<td>irregular amorphic</td>
<td></td>
<td>45–1180</td>
<td>Contour®</td>
<td>Boston Scientific Cooperation</td>
</tr>
<tr>
<td>starch particles</td>
<td>spherical</td>
<td></td>
<td>50</td>
<td>EmboCept®</td>
<td>PharmaCept</td>
</tr>
<tr>
<td>PVA particles</td>
<td>spherical</td>
<td></td>
<td>100–1200</td>
<td>Contour SE®</td>
<td>Boston Scientific Cooperation</td>
</tr>
<tr>
<td>PVA hydrogel particles</td>
<td>spherical</td>
<td></td>
<td>100–700</td>
<td>LC Bead®</td>
<td>AngioDynamics</td>
</tr>
<tr>
<td>PVA hydrogel particles</td>
<td>spherical</td>
<td></td>
<td>100–1200</td>
<td>Bead Block®</td>
<td>Terumo</td>
</tr>
<tr>
<td>Tris-acryl gelatin microspheres (TAGM)</td>
<td>spherical</td>
<td></td>
<td>40–1200</td>
<td>Embospheres®</td>
<td>Merrit Medical Systems</td>
</tr>
<tr>
<td>hydrogel particles with Polyzene®-F coating</td>
<td>spherical</td>
<td></td>
<td>40–1300</td>
<td>Embozene®</td>
<td>CeloNova Biosciences</td>
</tr>
</tbody>
</table>

**embolization coils**

<table>
<thead>
<tr>
<th>size [mm]</th>
</tr>
</thead>
<tbody>
<tr>
<td>stainless steel („stainless steel“)</td>
</tr>
<tr>
<td>nitinol</td>
</tr>
<tr>
<td>platinum</td>
</tr>
</tbody>
</table>

**Fig. 8**  Left bronchial artery in a patient with left pulmonary hypervascularized metastases of a thyroid carcinoma before and after peripheral PVA particle and proximal micro coil embolization.

**Abb. 8**  Linke Bronchialarterie bei links-pulmonalen hypervasularisierten Metastasen eines Schilddrüsenkarzinoms vor und nach PVA-Partikel- sowie proximaler Mikrospiralen-Embolisation.
sion of recurrent hemoptysis resulting from using PVA particles (355–500 μm and 500–710 μm) compared to gelatin sponges (1 mm³) is significantly greater (62–63 % vs. 45 %) [99]. However, the technical and primary success rate (up to 1 month post-BAE) for both particle types did not differ [99]. In this study, results were not dependent on particle size (355–500 μm vs. 500–710 μm). In addition, particles >350 μm appeared to reduce the risk of spinal complications, since they were too large to be used for embolization of small vessels supplying the spine [58]. In experimental studies smaller particles (<250 μm) or the use of ethanol frequently lead to bronchial wall necrosis resulting from a blockage of the bronchopulmonary anastomoses and subsequent obstruction of capillary perfusion of the bronchial walls [100–102]. Given the shared vascular supply to the esophagus or pulmonary arterial walls and aorta via the bronchial arteries, there is a risk of disastrous necrosis of the walls of the esophagus, pulmonary arteries and aorta [4]. The use of N-butyl-2-cyanoacrylate (NBCA (Histoacryl®)) is the subject of controversy in the literature. In earlier studies an increased risk of misembolization was attributed to liquid embolization material due to uncontrolled reflux or remnants of NBCA on the catheter tip [103, 104]; however, current studies have shown that liquid materials exhibit better long-term occlusion of the bronchial arteries without an increased rate of complications compared to PVA particles (non-recurrence of hemoptysis 5 years post-BAE: 83 % vs. 66 %) [105]. In this case, NBCA was diluted in a ratio of 1:2 to 1:4 with iodinated oily X-ray contrast agent Lipiodol® and applied super-selectively. Although the authors refer to the potential risks of a liquid embolise, they could not ascertain this in their study of the practical employment of NBCA for bronchial artery embolization. Increased rates of post-BAE complications such as bronchial or aortic wall necrosis, pulmonary parenchymal ischemia could likewise not be established [103–106]. However, it should be emphasized that when using liquid embolisates such as NBCA, extreme caution should be exercised, and that the risk of misembolization, particularly in spinal branches can be significantly increased if the interventionist is insufficiently experienced. Due to their size, embolization coils cause proximal occlusion of the bronchial artery. In the event of recurrent bronchial artery hemoptysis, this can obstruct reinterconnection into the periphery of the BA (e.g. repeated particle embolization) if there is reconstitution and perfusion of the pulmonary artery vascular bed by mediastinal or bronchial collaterals. PAVMs should be treated with targeted removable stainless steel embolization coils or balloons, analogous to the treatment of Rasmussen aneurysms in which the afferent pulmonary artery feeders are closed off [107–111].

**Conclusions**

The goal of the treatment of life-threatening massive hemoptysis is to control and stop bronchial artery bleeding. Numerous studies have proven the effectiveness and success of bronchial artery embolization. In recent decades the primary success rate of BAE has been continuously increased by improvements of catheter and embolization material so that in this time period the success rate up to 1 month post-BAE is 73–99 % (Table 3). On the other hand, in the longer term, lower BAE success rates for the treatment of hemoptysis have been recorded. Thus, studies of the 1–46 month post-treatment time frame show a recurrence of hemoptysis in 10–55 % of cases (Table 3). However, it should be kept in mind that although bronchial artery embolization successfully treats hemoptysis as a symptomatic intervention, it cannot eliminate the underlying cause. For this reason, causal therapy after a successful BAE is required to ensure the long-term success of the embolization. Depending upon the source of the hemoptysis, therapy can include antibiotics (for TB, aspergilloma), or elective surgical local resection (for bronchial carcinoma, chronic TB, aspergilloma) [95, 112]. Aspergilloma, in particular, may have poor outcomes with recurrent bleeding rates of up to 100 % and 50 % mortality rates within the first month after bronchial artery bleeding [113]. Therefore after repeated bronchial artery embolization, aggressive surgical approaches should be used to eliminate infection [11, 114–116]. If this does not succeed, recurrence of hemorrhaging within 2–5 years is highly likely [15, 113]. Recurrent hemoptysis after BAE can be caused pathomechanically by incomplete embolization, recanalization of the embolized bronchial artery, collateralization by other arterial vascular territories, inadequate causal therapy or progression of the underlying pulmonary disease [3, 4, 59, 95, 114]. It should be emphasized that all possible blood vessels supporting bronchial artery bleeding must be identified and embolized, especially including extrabronchial systemic arterial and pulmonary arterial vessels. It must also be stressed that the avoidance of recurrent hemoptysis is not the sole clinical success parameter. A retrospective study showed that adult patients receiving bronchial artery embolization following recurrent or massive hemoptysis exhibited significantly reduced pulmonary function with an increased transplant rate as well as higher mortality without recurrent massive hemoptysis compared to patients who had not undergone BAE [117].

**Table 3** Success and recurrence rate after BAE (from Chun et al. [90]).

<table>
<thead>
<tr>
<th>authors</th>
<th>year</th>
<th>number of patients</th>
<th>immediate success rate (up to 1 month post-BAE) in %</th>
<th>recurrence rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remy et al. [10]</td>
<td>1977</td>
<td>49</td>
<td>84 %</td>
<td>28.6 %</td>
</tr>
<tr>
<td>Rabkin et al. [37]</td>
<td>1987</td>
<td>306</td>
<td>90.8 %</td>
<td>33.7 %</td>
</tr>
<tr>
<td>Hayakawa et al. [68]</td>
<td>1992</td>
<td>58</td>
<td>86.2 %</td>
<td>28 %</td>
</tr>
<tr>
<td>Ramakantan et al. [61]</td>
<td>1996</td>
<td>140</td>
<td>73 %</td>
<td>27.1 %</td>
</tr>
<tr>
<td>Mal et al. [14]</td>
<td>1999</td>
<td>56</td>
<td>77 %</td>
<td>55.3 %</td>
</tr>
<tr>
<td>Swanson et al. [91]</td>
<td>2002</td>
<td>54</td>
<td>94 %</td>
<td>24.1 %</td>
</tr>
<tr>
<td>Poyanli et al. [58]</td>
<td>2007</td>
<td>140</td>
<td>98.5 %</td>
<td>10 %</td>
</tr>
<tr>
<td>Lee et al. [92]</td>
<td>2008</td>
<td>70</td>
<td>99 %</td>
<td>26 %</td>
</tr>
<tr>
<td>Chun et al. [79]</td>
<td>2009</td>
<td>50</td>
<td>86 %</td>
<td>28 %</td>
</tr>
</tbody>
</table>

**Complications**

Due to the collateral circulation of the bronchial arteries in other tissue territories (esophagus, visceral pleura, vasa vasorum of the aorta, pulmonary arteries and veins, and particularly the spinal arteries) misembolization can have fatal results. The most frequent side effects of BAE are transient chest pain (24–91 %) and/or dysphagia (0.7 %–18.2 %) [86, 118, 119] probably caused by occlusion of intercostal or esophageal branches. The subintimal short segment dissection of the aorta or bronchial artery has been indicated with a prevalence of 1 to 6.3 %, but is frequently non-symptomatic, and generally requires no additional remedies [11, 12, 14, 15, 96]. A particularly feared complication, generally

---

Ittrich H et al. Radiologic Management of... Fortschr Röntgenstr 2015; 187: 248–259

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
based on the toxicity of the contrast agent formerly in use, is transverse myelitis caused by spinal cord ischemia as a conse-
quencing of embolization of spinal branches or particle emboliz-
ation in the vicinity of the ostium with aorto–spinal particle dislo-
cation. A prevalence of 1.4–6.5% has been reported [14, 86, 88, 89, 97]. The risk of this type of spinal event is significantly re-
duced by a superselective BAE of terminal bronchial artery bran-
ches distal to vessels supporting the anterior spinal arteries [97]. Necrosis of the bronchial or aortic walls, transient cortical blind-
ness, ischemic colitis, pulmonary infarction or bronchial-esophage-
gal fistulas are rare complications of BAE [101, 120 – 123].

Summary

Hemoptysis represents a life-threatening pulmonary emergency and necessitates immediate diagnosis and therapy. Initial diagno-
sis using a conventional chest X-ray, contrast-supported multi-
slice computer tomography (MSCT) with CT angiography (CTA) of the thorax as well as bronchoscopy are required to determine the cause of hemoptysis, side localization, detection of abnormal bronchial and extrabronchial vessel branches; these also serve to support planning of interventional endovascular intervention in the form of bronchial artery embolization (BAE). BAE has estab-
lished itself as a first-line therapy for the treatment of massive and recurring hemoptysis or as a preparation for elective surgical therapy. Bronchial artery embolization should be considered a safe procedure when performed by an experienced endovascular interventionist with profound knowledge of potential pitfalls of the method. Recurrent hemoptysis after BAE is not unusual and likewise requires prompt embolization after investigation of end-
obronchial systemic or pulmonary bleeding sources.

References

5 Fernando HC, Stein M, Benfield JR et al. Role of bronchial artery em-
6 Knott-Craig CJ, Ostuzzi JC, Rossouw G et al. Management and prog-
10 Remy J, Arnaud A, Fardou H et al. Treatment of hemoptysis by emboli-
11 Ulfaker R, Koemmerer A, Neves C et al. Management of massive he-
mothysis by bronchial artery embolization. Radiology 1983; 146: 627 – 634
13 Keller FS, Rosch J, Loflin TG et al. Nonbronchial systemic collateral ar-
teries: significance in percutaneous embolotherapy for hemoptysis. Radi-
ology 1987; 164: 687 – 692
14 Mal H, Rullon I, Mellot F et al. Immediate and long-term results of bron-
16 Jean-Baptiste E. Clinical assessment and management of massive he-
18 Williams JR, Wilcox WC, Burns RR. Angiography of the Systemic Pulmo-
21 Reuter SR, Olin T, Abrams HL. Selective Bronchial Arteriography. Radiol-
ogy 1965; 84: 87 – 95
23 Feigelson HH, Ravin HA. Transverse myelitis following selective bron-
chial arteriography. Radiology 1965; 85: 663 – 665
24 Kardjevic V, Symonov A, Chankov I. Etiology, pathogenesis, and preven-
tion of spinal cord lesions in selective angiography of the bronchial and intercostal arteries. Radiology 1974; 112: 81 – 83
25 Remy J, Voisin C, Dupuis C et al. Treatment of hemoptysis by emboli-
zytic of the systemic circulation. Ann Radiol (Paris) 1974; 17: 5 – 16
28 Defebvre ME, Charan NB, Lakshminarayan S et al. The bronchial circu-
30 Lee ST, Kim SY, Hur G et al. Coronary-to-bronchial artery fistula: de-
monstration by 64-multidetector computed tomography with retro-
spective electrocardiogram-gated reconstructions. Journal of compu-
ter assisted tomography 2008; 32: 444 – 447
31 Lee CM, Leung TK, Wang HJ et al. Identification of a coronary-to-bron-
chial-artery communication with MDCT shows the diagnostic poten-
32 Bas S, Yiginer O, Atalay M et al. Coronary-to-bronchial artery fistula with conventional and multi-detector computed tomography angi-
ographic images. Hellenic journal of cardiology: HJC – Hellenic cardiol-
ogike epiteroseis 2010; 51: 164 – 165
34 Moon MH, Kang JK, Song H. Acquired coronary-to-bronchial artery fis-
35 Eryilmaz U, Gungor H, Uyar S et al. Circumflex-to-bronchial artery fis-
36 Battal B, Saglam M, Ors F et al. Aberrant right bronchial artery originat-
ing from right coronary artery – MDCT angiography findings. Br J Radi-
ol 2010; 83: e101 – e104
37 Oz F, Erdogan I, Oflaz H et al. Bifid origin of the right coronary artery, co-
40 Peynicoglu B, Ergun O, Haziroglu T et al. Bronchial to coronary artery fis-
tulas: an important sign of silent coronary artery disease and poten-

Iltrich H et al. Radiologic Management of... Forschr Röntgenstr 2015; 187: 248 – 259


Cohen AM, Doershuk CF, Stern RC. Bronchial artery embolization to control hemoptysis in cystic fibrosis. Radiology 1990; 175: 401–405


